 Adenocarcinomas of the esophagus and the esophagogastric junction AEG are clinically-topographically divided into subtypes I-III according to the Siewert classification and show an increased incidence. Neoadjuvant andor perioperative chemotherapy or preoperative radiochemotherapy is well established in the management of AEG. However, a significant number of patients do not respond to preoperative chemotherapy, suffering from toxicity and facing a worse outcome due to lower R0 resection rates. Previous results from the MUNICON-1 and MUNICON-2 trials have shown that PET-based therapy individualization can be successfully integrated in neoadjuvant treatment algorithms. 